Lixte Biotech Hldgs (LIXT) 0.2500 $LIXT
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Fri Jan 23, 8:04AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB--100, is being conducted, has been expanded from 1 to 5 institutions.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.84 (unch), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), PVCT: 0.79 (-0.02), CANF: 3.85 (+0.05), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), XLRN: 38.02 (+0.07)
Brain Ischemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttpc9j/brain_ischemia) has announced the addition of the "Brain Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Edge - FibroGen - Immune - Lixte Biotechnology Holdings, - Medestea Research & Production - NeuroNascent, - NeurOp - Spectrum - Sylentis - The International Biotechnology Center (IBC) For more information visit http://www.researchandmarkets.com/research/tt...n_ischemia
Lixte Biotech: A Novel Approach to Boost Existing Cancer Therapies
ACCESSWIRE - Tue Nov 18, 10:05AM CST
WHITEFISH, MT / ACCESSWIRE / November 18, 2014 / Cellular signaling is a complex system of communication that governs basic cellular activities and coordinates cell actions. In many cases, errors in cellular information processing are responsible for diseases like cancer, autoimmune disorders, and diabetes. Researchers are attempting to understand these cellular signaling pathways to effectively treat these disorders and accomplish other medical feats.
SGEN: 31.57 (+0.36)
Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
PR Newswire - Thu Nov 06, 9:00AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer, has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, LB-100. For more information, see: http://www.iirusa.com/therapeuticareapartners...ingcos.xml
Gaucher's Disease - Pipeline Review, H1 2014
M2 - Thu Jul 03, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p99kr2/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme Corporation - Sangamo BioSciences, Inc. - Shire Plc - Amicus Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Protalix BioTherapeutics, Inc. - JCR Pharmaceuticals Co., Ltd. - greenovation Biotech GmbH - Neuraltus Pharmaceuticals, Inc. - Biosidus S.A. - ExSAR Corporation - Bioorganic Research and Services S.A. - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/p9...rs_disease
SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14), FOLD: 8.36 (-0.11)
Neurofibromatoses Type II - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vq8st6/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Lixte Biotechnology Holdings, Inc. - Arno Therapeutics, Inc. - Nexgenix Pharmaceuticals, LLC - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/vq...bromatoses
Medulloblastoma - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ld2gzs/medulloblastoma) has announced the addition of the "Medulloblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medulloblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - Archer Biosciences - Conkwest - Lixte Biotechnology Holdings - Novartis - Stemline Therapeutics - Takeda Pharmaceutical - TheraBiologics - ThromboGenics For more information visit http://www.researchandmarkets.com/research/ld...loblastoma
STML: 14.07 (-0.10), NVS: 102.20 (-0.17)
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Fri Jan 23, 8:04AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB--100, is being conducted, has been expanded from 1 to 5 institutions.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.84 (unch), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), PVCT: 0.79 (-0.02), CANF: 3.85 (+0.05), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), XLRN: 38.02 (+0.07)
Brain Ischemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttpc9j/brain_ischemia) has announced the addition of the "Brain Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Edge - FibroGen - Immune - Lixte Biotechnology Holdings, - Medestea Research & Production - NeuroNascent, - NeurOp - Spectrum - Sylentis - The International Biotechnology Center (IBC) For more information visit http://www.researchandmarkets.com/research/tt...n_ischemia
Lixte Biotech: A Novel Approach to Boost Existing Cancer Therapies
ACCESSWIRE - Tue Nov 18, 10:05AM CST
WHITEFISH, MT / ACCESSWIRE / November 18, 2014 / Cellular signaling is a complex system of communication that governs basic cellular activities and coordinates cell actions. In many cases, errors in cellular information processing are responsible for diseases like cancer, autoimmune disorders, and diabetes. Researchers are attempting to understand these cellular signaling pathways to effectively treat these disorders and accomplish other medical feats.
SGEN: 31.57 (+0.36)
Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
PR Newswire - Thu Nov 06, 9:00AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer, has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, LB-100. For more information, see: http://www.iirusa.com/therapeuticareapartners...ingcos.xml
Gaucher's Disease - Pipeline Review, H1 2014
M2 - Thu Jul 03, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p99kr2/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme Corporation - Sangamo BioSciences, Inc. - Shire Plc - Amicus Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Protalix BioTherapeutics, Inc. - JCR Pharmaceuticals Co., Ltd. - greenovation Biotech GmbH - Neuraltus Pharmaceuticals, Inc. - Biosidus S.A. - ExSAR Corporation - Bioorganic Research and Services S.A. - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/p9...rs_disease
SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14), FOLD: 8.36 (-0.11)
Neurofibromatoses Type II - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vq8st6/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Lixte Biotechnology Holdings, Inc. - Arno Therapeutics, Inc. - Nexgenix Pharmaceuticals, LLC - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/vq...bromatoses
Medulloblastoma - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ld2gzs/medulloblastoma) has announced the addition of the "Medulloblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medulloblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - Archer Biosciences - Conkwest - Lixte Biotechnology Holdings - Novartis - Stemline Therapeutics - Takeda Pharmaceutical - TheraBiologics - ThromboGenics For more information visit http://www.researchandmarkets.com/research/ld...loblastoma
STML: 14.07 (-0.10), NVS: 102.20 (-0.17)
